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Objective: To determine the physiological impact of treatment with donepezil (Aricept)
on neural circuitry supporting episodic memory encoding in patients with amnestic mild
cognitive impairment (MCI) using functional magnetic resonance imaging (fMRI).
Methods: Eighteen patients with MCI and 20 age-matched healthy controls (HC) were
scanned twice while performing an event-related verbal episodic encoding task. MCI par-
ticipants were scanned before treatment and after approximately 3 months on donepezil;
HC were untreated but rescanned at the same interval.Voxel-level analyses assessed treat-
ment effects on activation profiles in MCI patients relative to retest changes in non-treated
HC. Changes in task-related connectivity in medial temporal circuitry were also evaluated,
as were associations between brain activation, task-related functional connectivity, task
performance, and clinical measures of cognition.
Results: At baseline, the MCI group showed reduced activation during encoding relative
to HC in the right medial temporal lobe (MTL; hippocampal/parahippocampal) and addi-
tional regions, as well as attenuated task-related deactivation, relative to rest, in a medial
parietal lobe cluster. After treatment, the MCI group showed normalized MTL activation
and improved parietal deactivation. These changes were associated with cognitive perfor-
mance. After treatment, the MCI group also demonstrated increased task-related functional
connectivity from the right MTL cluster seed region to a network of other sites including
the basal nucleus/caudate and bilateral frontal lobes. Increased functional connectivity was
associated with improved task performance.
Conclusion: Pharmacologic enhancement of cholinergic function in amnestic MCI is asso-
ciated with changes in brain activation and functional connectivity during episodic mem-
ory processing which are in turn related to increased cognitive performance. fMRI is a
promising biomarker for assessing treatment related changes in brain function.
Keywords: functional magnetic resonance imaging, mild cognitive impairment, donepezil (Aricept), Alzheimer’s
disease, task-related functional connectivity, episodic encoding
INTRODUCTION
Alzheimer’s disease (AD) is the most common age-related neu-
rodegenerative disease, affecting millions of older adults world-
wide (1). AD is characterized by declining cognitive function,
impaired activities of daily living (ADL), and dementia (2).
Amnestic mild cognitive impairment (MCI), which features an
isolated impairment in memory with relative sparing of other
cognitive domains and daily functioning, is considered to be a
prodromal stage of AD with an annualized MCI to AD conversion
rate of 10–15% (3, 4).
Currently only a few medications are approved for use in
patients with AD, although many others are under intensive inves-
tigation. The primary FDA-approved therapeutic agents for mild
to moderate AD are cholinesterase inhibitors (ChEIs), includ-
ing donepezil (Aricept), rivastigmine (Exelon), and galantamine
(Razadyne, formerly Reminyl). Tacrine (Cognex) the first
approved agent of this class has been discontinued. Meman-
tine (Namenda), a glutamatergic NMDA-receptor blocker, is also
approved for treatment of moderate to severe AD patients. Effec-
tiveness of these medications in AD has been demonstrated,
including mild to moderate improvement of cognition (5),
although these effects may be only temporary. However, studies
of ChEIs in MCI have shown mixed results at best and currently
ChEI treatment is not recommended for MCI (6).
Functional magnetic resonance imaging (fMRI) is a technique
which allows for measurement of brain function under a variety of
conditions (at rest, during tasks, after drug administration, etc.).
Blood oxygen level dependent (BOLD) contrast fMRI assesses rel-
ative changes in blood deoxyhemoglobin concentration to provide
information on relative activation or deactivation of specific brain
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regions. Pharmacologic fMRI involves the utilization of BOLD
fMRI techniques to assess the effects of pharmacologic agents on
regional and global brain activation. This technique has been used
in a variety of conditions and with a variety of pharmacologic
interventions (7–14).
In patients with MCI and AD, pharmacologic treatment with
ChEIs has been evaluated using task-related and resting-state
fMRI (10, 15–33). In AD patients, acute dosing with ChEIs
resulted in primarily increased activation post-drug treatment
during episodic face encoding and recognition, working mem-
ory, and visual and attention tasks in task-related regions (15,
19, 22, 29). Chronic dosing of AD patients with ChEIs for vary-
ing periods (10–24 weeks) also showed a post-drug effect on
brain activation,with patients showing increased activation during
episodic encoding and recognition, semantic association, work-
ing memory, and visuospatial perceptual tasks in task-related
areas (18, 21, 27, 29). Increased activation in task-related regions
during episodic encoding after ChEI treatment in AD patients
was also associated with improved clinical memory performance
(31). Alternatively, a few studies have shown decreased activa-
tion in task-related regions after prolonged (5 days) or chronic
(12–20 weeks) treatment with ChEIs in AD patients during visual
perceptual tasks, such as face matching and location matching
(23), episodic encoding and recognition (19), as well as dur-
ing semantic association and working memory tasks (34). Fur-
ther, AD patients who did not show improved cognition after
chronic dosing with ChEI (“non-responders”) showed mostly
decreased activation post-drug in task-related areas during seman-
tic association and working memory tasks, while patients who
showed improved cognition after ChEI treatment (“respon-
ders”) showed primarily increased activation during these tasks
in task-specific regions (25). Finally, resting-state fMRI studies
in AD patients treated with chronic ChEIs showed increased
functional connectivity in a hippocampal network, a cingu-
late network, and the default mode network (DMN) post-drug
treatment (28, 30, 33).
Only a few studies have evaluated ChEI treatment effects on
fMRI brain activation in MCI patients. Acute dosing of MCI
patients with ChEIs results in increased activation post-drug in
task-specific regions during episodic encoding and recognition
(19), while prolonged treatment (5–7 days) resulted in increased
activation post-drug during episodic encoding, working memory,
and spatial navigation tasks (16, 20). When comparing AD and
MCI patients after acute ChEI dosing, MCI patients demonstrated
increased activation during face recognition after treatment, while
AD patients showed increased activation during face encoding
(19). On the other hand, one study demonstrated decreased acti-
vation during episodic encoding and recognition in task-related
regions after more prolonged (5 days) dosing with galantamine in
MCI patients (19). Chronic ChEI treatment (11–24 weeks) in MCI
patients primarily results in increased activation in task-related
regions post-drug during working memory, episodic encoding,
and episodic recognition tasks (17, 24, 32). Pa et al. (32) also
evaluated functional connectivity during episodic encoding and
demonstrated increased connectivity in a fusiform network after
chronic treatment with donepezil relative to untreated MCI
patients (32).
Although results have been mixed, the administration of ChEIs
in patients with MCI and AD generally enhances brain activation
in task-dependent regions and brain connectivity measured dur-
ing resting-state fMRI. However, to date no study has evaluated
changes in brain activation and task-related functional connec-
tivity during an auditory verbal episodic memory task in MCI
patients after treatment with donepezil, as all previous stud-
ies have used visual encoding tasks. Furthermore, no study has
evaluated changes in brain activation and connectivity during
episodic encoding relative to changes over the same time period
in a healthy control (HC) population. The overall goal of the
present study was to evaluate the effect of a 3-month treatment
period with donepezil (Aricept) on memory circuitry activation
pattern and connectivity during episodic memory encoding in
MCI patients using event-related fMRI, as well as the relation-
ship between these fMRI measures and cognition before and
after treatment. We hypothesized that MCI patients would show
increased activation in task-related regions (e.g., hippocampus),
as well as greater deactivation in regions of the DMN (e.g.,
precuneus/posterior cingulate cortex), after donepezil treatment.
In addition, we hypothesized that increased activation in task-
dependent regions and greater deactivation in the DMN would
be associated with better cognitive performance. We also hypoth-
esized that MCI patients would show improved task-related func-
tional connectivity in cholinergic networks associated with the
hippocampus and episodic encoding. Finally, we hypothesized that
increased functional connectivity in task-related regions would be
associated with improved cognition.
MATERIALS AND METHODS
PARTICIPANTS
Participants included 18 patients diagnosed with amnestic MCI
and 20 age-matched HC recruited as part of a larger study on brain
aging. In the present study, participants were diagnosed as amnes-
tic MCI if they had a combined verbal memory performance on
three measures from the California Verbal Learning Test (CVLT)
(35, 36) and two measures from the Weschler Memory Scale-III
(WMS-III) (37) Logical Memory subtest which fell more than
one standard deviation below the performance of the HC group
mean, after adjustment for age, education level, and gender. MCI
participants were further classified using the recent distinction of
early and late MCI [EMCI, LMCI; Ref. (38)] as follows: (1) EMCI
patients had a 1–1.49 SD deficit in episodic memory performance;
and (2) LMCI patients had a 1.50 SD or greater deficit. In this sam-
ple of 18 MCI participants, 2 were classified as EMCI and 16 were
classified as LMCI. Further analysis of the difference between these
groups demonstrated no significant effect of MCI stage on fMRI
activation after donepezil treatment, although the comparison was
underpowered due to the small group sizes. Thus, in the present
study all MCI participants were combined into a single MCI group.
In addition, diagnoses for all participants were reviewed on a case-
by-case basis using a multidisciplinary consensus approach and
applying the Petersen MCI criteria (2, 3) and the Clinical Dementia
Rating (CDR) scale (39). Additional information about partic-
ipant recruitment, exclusion and inclusion criteria, and study
design is available in previous reports (17, 40). All participants
provided written informed consent according to the Declaration
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of Helsinki and all procedures were approved by the Dartmouth
College Committee for the Protection of Human Subjects.
DONEPEZIL PROTOCOL
All MCI patients were cholinesterase inhibitor naïve prior to treat-
ment. In addition, we excluded any participants taking other
medications that could affect cognition, hemodynamic response
in the scanner, and/or cholinergic function. Initially, patients with
MCI were provided information on treatment options and all
included participants elected to start treatment with donepezil
hydrochloride. Participants were carefully monitored by a geriatric
psychiatrist (RBS). Participants were started on a 5 mg dose, which
was increased to 10 mg after approximately 4 weeks. Reported
side effects included mild gastrointestinal symptoms, sleep distur-
bance, and leg cramps, which are all well-known for this class of
medication. No unexpected or serious adverse effects occurred in
this study. One participant discontinued donepezil just prior to the
second scanning session and initiated treatment with galantamine
(Reminyl). All other MCI participants remained on donepezil
through the second scan session. At the time of the second scan ses-
sion, MCI participants were on donepezil for an average of 90.75
(±27.76) days, of which they received 10 mg of donepezil for 54.83
(±22.63) days.
CLINICAL AND NEUROPSYCHOLOGICAL ASSESSMENTS
All participants underwent a comprehensive clinical and neu-
ropsychological battery. Psychometric tests included, but were not
limited to: the Mini-Mental State Exam (MMSE) (41, 42), the Mat-
tis Dementia Rating Scale (DRS) (43), the CVLT [sum of trials 1–5
(total), Short Delay Free Recall, and Long Delay Free Recall] (35,
36), and WMS-III Logical Memory Immediate and Delayed Recall
(37). In addition, both the participant and an informant were
given measures to assess cognitive complaints, which are detailed
in a previous report (40). These include a Memory Assessment
Questionnaire (40), which is adapted in part from the Functional
Activities Questionnaire (44), the Memory Self-Rating Question-
naire (45), the self and informant versions of the Neurobehavioral
Function and ADL Rating Scale (46), self and informant versions
of the Questionnaire on Cognitive Decline in the Elderly (47),
four cognitive items from the Geriatric Depression Scale (GDS)
(48), and 10 cognitive items from a telephone-based screening for
MCI (49). A cognitive complaint index (CCI) was calculated as the
percentage of all items endorsed as a complaint for each partici-
pant and his or her informant independently, as well as across all
metrics (self and informant) (40). Finally, depressive symptoms
were assessed using the GDS. Since the MCI patient population is
known to have complaints about memory, we utilized an adjusted
GDS score to measure depression, which subtracts from the total
score the endorsement of items pertaining to cognitive difficulty,
if applicable.
fMRI SCANNING PROTOCOLS AND PRE-PROCESSING
Healthy control and MCI participants were scanned twice, with
an average interval between scans of 111.8 (±30.0) days. All scans
were completed on a GE Signa 1.5 T Horizon LX scanner with
echo speed gradients using a standard RF coil. Specific fMRI para-
meters were as follows: TR= 2500 ms, TE= 40 ms, FOV= 24 cm,
NEX= 1. This scanning protocol resulted in 29 contiguous 5 mm
sagittal slices in a 64× 64 matrix with an in-plane resolution of
3.75 mm2.
The administered task was an auditory event-related continu-
ous performance episodic recognition memory task (12, 50, 51).
This task design was adapted from an ERP paradigm that had dif-
ferentiated medial temporal and frontal contributions to episodic
memory (52) and consists of a list of words with a pseudoran-
dom jittered interstimulus interval of 5–8 s and a total task time
of 330 s. Each word is presented twice, with the second presen-
tation either immediately following the first (within three words,
“working memory” recognition condition), or nine or more items
later (“long delay” recognition condition) (Figure 1). The partici-
pant responds by button press to each presented word, indicating
whether the stimulus is being presented for the first time (“new”)
or the second time (“old”). Epochs of rest, in which no word is
presented, are also present in the task sequence. Analysis is per-
formed by dividing data into four event types: “rest” (no word
presentation),“new”(which is considered an encoding condition),
“working memory,” and “long delay”. The “working memory” and
“long delay” conditions are also concatenated into a single “old”
condition. Contrasts are then made to compare hemodynamic
response functions for each of these conditions. In order to eval-
uate episodic encoding, the contrasts evaluated in the present
analysis include:“new”greater than“old”(NEWgtOLD) and“new”
greater than “rest” (NEWgtREST). Response accuracy and reac-
tion time for each condition were also evaluated. Prior to the
scans, participants rehearsed alternate version of the task out-
side the scanner to ensure understanding of the instructions and
task requirements. All participants demonstrated sufficient task
comprehension before scanning.
After quality control to rule out scanning artifacts and/or exces-
sive motion, all fMRI data were pre-processed using standard pro-
cedures in the Statistical Parametric Mapping package (SPM5)1.
Briefly, scans were spatially aligned to remove any motion-related
signal change, normalized to a standard space atlas [Montreal Neu-
rologic Institute (MNI)], resampled to 2 mm3 isotropic voxels, and
smoothed to a full width at half maximum of 8 mm. Two runs of
equivalent alternate forms of the task were completed for each
participant at each scanning session and the both the fMRI and
performance results were averaged across the two runs for fur-
ther analysis. Two participants failed quality control for one of
the two task trials and thus, only one trial was used for these
two participants in analyses. Contrast images were created using
random effects analyses for the target comparisons (NEWgtOLD,
NEWgtREST) and analyzed as described below.
TASK-RELATED REGION OF INTEREST CONNECTIVITY ANALYSIS
Task-related functional connectivity was assessed using an updated
version of previously published psychophysiological interaction
(PPI) analysis methods (53). This approach evaluates how regional
network activation covaries in relation to a target region of interest
(ROI) during the episodic memory task (54–56). A seed region was
delineated as a significant cluster within the right medial temporal
1http://www.fil.ion.ucl.ac.uk/spm/
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FIGURE 1 | Continuous verbal episodic memory task. The episodic
memory task used in the present study features continuous encoding and
recognition of simple words. The participant responds to each item by
indicating whether it is a new item (not previously heard) or an old item
(previously heard). The new items represent episodic encoding, as the
participant must encode these items for possible future presentation. The
old items represent episodic recognition and are divided into working
memory items (WM), where the item was presented one to three words
prior to the recognition episode, and long delay memory items, where the
target item was presented nine or more words prior to the recognition item
event. See the text for further description of this task.
lobe that was identified in the group-by-time comparisons of fMRI
activation from the primary contrast to detect episodic encoding
activation (NEWgtOLD). First, the drift effect was extracted from
the time series using AFNI 3dSynthesize2 and then the temporal
trend was removed. After that, averaged time series of the seed
region were deconvolved with a gamma variant model to generate
the first regressor for the PPI analysis (54). A general linear model
was then constructed for each participant using three regressors:
(1) the physiological variable, represented by the deconvolved bold
signal from the seed region, (2) the psychological variable, repre-
sented by the task condition type (encoding, coded 1 for new
events and 0 for old events) and (3) the interaction term between
the first and the second regressor. Contrasts for this interaction
term revealed brain regions considered to covary as a functional
network with the seed region for each participant (54, 55).
STATISTICAL ANALYSES
Contrast images were compared between diagnostic groups (HC
and MCI) on a voxel-by-voxel basis in SPM8. We used SPM8 due to
the ease of navigating results. However, the same analysis in SPM5
generated nearly identical results. We first compared the effect of
diagnostic group (HC vs. MCI) at each of the two timepoints
(baseline and follow-up). In addition, since we were interested in
the effects of donepezil on brain activation in the MCI group,
an interaction between group and time (baseline and follow-up)
was evaluated. All analyses used a whole-brain mask and were
displayed at a voxel-wise threshold of p< 0.01 (uncorrected) and
2http://afni.nimh.nih.gov/
minimum cluster size (k)= 50 voxels. However, note that in all
reported clusters many of the local maxima met a voxel-wise signif-
icance threshold of p< 0.001 (uncorrected; see Tables A1 and A2
in Appendix). In summary, for each contrast condition (NEWg-
tOLD, NEWgtREST), the following comparisons were evaluated:
two diagnosis group-by-time interactions (follow-up> baseline
for MCI>HC and for HC>MCI) and four cross-sectional analy-
ses (HC>MCI at baseline, HC>MCI at follow-up, MCI>HC
at baseline, MCI>HC at follow-up). In the present results, we
present results from selected analyses which demonstrated sig-
nificant and biologically relevant effects. Significant voxels and/or
clusters were reported in Tables A1 and A2 in Appendix if they had
a Z -value ≥3.5 or a cluster-wise significance of p< 0.05 (uncor-
rected) and a Z -value ≥3.0 (maximum of three local maxima
reported for each significant cluster). Anatomical labels for each
significant region were determined by converting the MNI coor-
dinates of the peak voxel to Talairach coordinates and evaluating
these coordinates using the Talairach Client (version 2.4)3. In addi-
tion, ROIs from two clusters of interest [right medial temporal
lobe cluster in NEWgtOLD, follow-up> baseline, MCI>HC (see
Figure 2C); medial parietal cluster from NEWgtREST, MCI>HC
at baseline (see Figure 4A)] were extracted for each participant’s
contrast images (NEWgtOLD, NEWgtREST, respectively) using
MarsBaR (57). Data were also extracted from each set of contrast
images using anatomical ROIs from the bilateral precentral and
postcentral gyri as control regions.
Task-related functional connectivity contrast maps were
assessed for the effect of diagnostic group and time using a two-
way general linear model in SPM8. Briefly, the effects of diagnostic
group and time were assessed, generating two interaction contrasts
(follow-up> baseline, MCI>HC, and HC>MCI). A whole-
brain mask was applied and a voxel-wise threshold of p< 0.01
(uncorrected) and k = 100 voxels was considered significant. Note
that all reported clusters contained multiple local maxima that
met a voxel-wise significance threshold of p< 0.001 (uncorrected;
see Table A3 in Appendix). Significant voxels and/or clusters were
reported in Table A3 in Appendix if they had a cluster-wise sig-
nificance of p< 0.05 (uncorrected) and Z -value≥3.0 (maximum
of three local maxima reported for each significant cluster). ROIs
were then generated from selected significant clusters identified in
the diagnostic group-by-time interaction analysis, including from
the left basal nucleus/caudate, left medial temporal lobe, and the
left frontal lobe. Mean task-related functional connectivity values
in the target ROIs were extracted from the contrast maps using
MarsBaR (57).
Demographics, APOE genotype, family history of dementia,
baseline neuropsychological performance, and baseline task per-
formance were compared between diagnostic groups (HC vs.
MCI) using an ANCOVA model in SPSS (version 20). Base-
line and follow-up fMRI activation values for target contrasts
(NEWgtOLD, NEWgtREST), as well task-related functional con-
nectivity measures from the extracted target ROIs were also com-
pared between diagnostic groups. Age, gender, and education
were included as covariates where appropriate (i.e., ROI values,
3http://www.talairach.org/client.html
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FIGURE 2 | Effects of diagnostic group and time on brain activation
during episodic encoding relative to episodic recognition. (A) HC
participants (n=20) showed significantly greater activation than MCI
patients (n=18) at baseline in the right medial temporal lobe (right
hippocampus and parahippocampal gyrus), along with other cortical and
subcortical regions. (B) No difference between MCI and HC participants
was seen in the medial temporal lobe after MCI participants underwent
approximately 3 months of donepezil treatment, although a few other
regions remained significant. (C)The interaction of diagnostic group-by-time
demonstrated that MCI patients showed a greater increase in brain
activation in the right medial temporal lobe after donepezil treatment relative
to HC. All panels are displayed at a voxel-wise threshold of p<0.01
(uncorrected) and a minimum cluster size (k )=50 voxels. However, most of
the observed clusters have local maxima that reach a voxel-wise threshold
of p<0.001 (uncorrected; seeTable A1 in Appendix). See the Section
“Results” and Table A1 in Appendix for additional results. FU= follow-up,
BL=baseline, MCI=mild cognitive impairment, HC= healthy older adults,
R= right, L= left.
neuropsychological, and task performance variables). Change
from baseline to follow-up in neuropsychological performance
and task performance was computed as the follow-up value minus
the baseline value. These change values were compared between
groups using an ANCOVA model, covaried for baseline age, gen-
der, and education. Repeated measures models were evaluated to
look at the interaction of diagnostic group-by-time on all target
ROI measures covaried for age, gender, and education.
The relationships between baseline and change in neuropsycho-
logical performance, task performance, and extracted ROI values
were assessed using a partial Pearson correlation model, covaried
for age, gender, and education (where appropriate), and a Spear-
man correlation model within the MCI group only. Specifically,
associations between baseline and change in neuropsychological
and task performance and target ROI values of fMRI activation
and connectivity at baseline, follow-up, and the change from base-
line to follow-up were evaluated. Only the associations that were
found to be significant using both the Pearson and Spearman cor-
relation models are presented. However, only the statistical results
for the Pearson correlations are reported.
RESULTS
DEMOGRAPHICS, NEUROPSYCHOLOGICAL, AND TASK PERFORMANCE
No significant differences were observed between MCI and HC
participants in age, gender, years of education,APOE ε4 genotype
carrier status, family history of dementia, or depressive symptoms
(Table 1). As expected, MCI and HC participants differed on all
clinically administered neuropsychological measures at baseline,
with MCI participants showing more impaired cognition than HC
(Table 1; p< 0.001). However, fMRI task performance (accuracy
and reaction time) did not differ between MCI and HC partici-
pants at baseline. Total, self, and informant cognitive complaints
were higher in the MCI patients than in HCs (Table 1; p< 0.001).
Between baseline and follow-up, MCI participants demonstrated a
significant improvement in CVLT total score relative to the change
in HC participants (Table 1; p< 0.001). In addition, MCI partic-
ipants had a greater decline in total and self cognitive complaints
after treatment (Table 1; p= 0.007 and 0.005, respectively). No
other significant differences between MCI and HC in psycho-
metric test performance change over the follow-up period were
observed. Change in task performance accuracy on long delay
items was significantly different between HC and MCI, with MCI
participants showing a mild accuracy decline and HC participants
showing a marked improvement (Table 1; p< 0.05). No other
changes in task performance measures were significantly different
between HC and MCI participants.
VOXEL-WISE COMPARISONS
The initial voxel-wise analysis considered the effect of diagnostic
group at baseline and follow-up independently. At baseline, HC
participants showed significantly more activation during encoding
(NEWgtOLD) than MCI patients in the right medial temporal
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Table 1 | Demographic information and neuropsychological performance.
HC (n=20) MCI (n=18) p-Value
Age (years) 71.4 (4.7) 72.3 (6.3) ns
Education (years) 17.1 (2.4) 16.3 (2.9) ns
Gender (M, F) 8, 12 10, 8 ns
APOE e4 positive (%)a 45.0 50.0 ns
Family history of dementia (% positive) 55.0 55.6 ns
Baseline average memory Z -scoreb 0.1 (0.6) −2.4 (0.7) <0.001
Baseline CDR – sum of boxesc 0.2 (0.2) 1.6 (0.8) <0.001
Baseline MMSE total scorec 29.1 (0.9) 26.6 (2.8) <0.001
Baseline DRS total scorec 140.8 (2.0) 136.7 (4.0) <0.001
Baseline CVLT total immediate scorec 49.3 (7.8) 30.1 (5.9) <0.001
Baseline CVLT short delay recall scorec 11.6 (2.1) 4.9 (2.1) <0.001
Baseline CVLT long delay recall scorec 12.0 (2.0) 5.4 (2.2) <0.001
Baseline Logical Memory immediate recallc 49.1 (6.9) 33.4 (8.7) <0.001
Baseline Logical Memory delayed recallc 32.4 (5.6) 19.0 (7.6) <0.001
Baseline GDS (adjusted)c 1.0 (1.6) 1.7 (1.9) ns
Baseline overall CCId,e 9.0 (4.7) 35.0 (14.2) <0.001
Baseline self CCId,e 13.0 (6.5) 43.4 (20.8) <0.001
Baseline informant CCId,e 3.8 (4.6) 26.5 (18.5) <0.001
Baseline task accuracy – new itemsc 96.7 (4.8) 93.9 (9.5) ns
Baseline task accuracy – WM itemsc 87.9 (17.7) 92.3 (7.1) ns
Baseline task accuracy – long delay itemsc 62.1 (21.7) 56.9 (22.3) ns
Baseline task accuracy – overallc 86.0 (8.1) 84.3 (7.1) ns
Baseline task reaction time – new itemsc (ms) 654 (559) 730 (520) ns
Baseline task reaction time – old itemsc (ms) 764 (514) 854 (471) ns
Change in MMSE total scorec 0.2 (1.3) 0.4 (1.5) ns
Change in DRS total scorec 0.9 (2.2) 1.5 (3.5) ns
Change in CVLT total immediate scorec −1.4 (6.0) 6.1 (5.3) <0.001
Change in CVLT short delay scorec −0.6 (2.7) 0.7 (3.0) ns
Change in CVLT long delay scorec −0.1 (2.4) 0.8 (3.4) ns
Change in overall CCId,e −3.8 (4.7) −12.3 (10.7) 0.003
Change in self CCId,e −5.3 (6.2) −16.8 (14.6) 0.003
Change in informant CCId,e −1.8 (4.3) −8.5 (12.0) 0.028
Change in task accuracy – new itemsc −1.1 (5.4) 2.0 (8.5) ns
Change in task accuracy – WM itemsc 6.6 (18.0) 0.5 (7.7) ns
Change in task accuracy – long delay itemsc 9.0 (18.3) −1.7 (23.0) 0.038
Change in task accuracy – overallc 3.2 (8.3) 0.7 (5.9) ns
Change in task reaction time – new itemsc (ms) −89 (762) −154 (678) ns
Change in task reaction time – old itemsc (ms) −175 (592) −178 (541) ns
aTwo MCI participants missing APOE genotype information.
bAverage memory Z-score is computed as follows: z-scores are calculated using the mean and standard deviation, adjusted for age, gender, and education, from
whole study healthy control group for the CVLT total immediate score, CVLT short delay recall score, CVLT long delay recall score, Logical Memory immediate recall,
and Logical Memory delayed recall; the average of these five z-scores represents the average memory Z-score.
cRaw values are presented but statistical tests include age, gender, and education as covariates.
dOne HC participant missing all CCI data (total, self, and informant).
eRaw values are presented; statistical tests do not include covariates.
HC, healthy control; MCI, mild cognitive impairment; M, male; F, female; ns, not significant; CDR, Clinical Dementia Rating scale; MMSE, Mini-Mental State Exam;
DRS, Mattis Dementia Rating Scale – version 2; CVLT, California Verbal Learning Test – version 2; GDS, Geratric Depression Scale; CCI, Cognitive Complaint Index;
WM, Working Memory; ms, milliseconds.
lobe (right hippocampus and parahippocampal gyrus), as well as
in the right cerebellum, right uncus, left superior frontal gyrus,
and the right superior temporal gyrus (Figure 2A; Table A1A in
Appendix). At follow-up, this difference between HC and MCI
participants in the right medial temporal lobe was not observed.
However, HC participants demonstrated greater activation than
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MCI in a number of other regions at follow-up that were not
different between the diagnostic groups at baseline, including in
the brainstem (medulla), right insula, bilateral precentral gyrus,
bilateral inferior parietal lobules, right caudate, left medial frontal
gyrus, and right putamen (Figure 2B; Table A1A in Appendix). A
continued difference between diagnostic groups was also observed
in the right cerebellum with HC participants showing greater acti-
vation than MCI patients. We then performed a voxel-wise analysis
to assess the effects of the interaction of diagnostic group-by-time
on activation during encoding (NEWgtOLD) and showed a num-
ber of significant clusters. At follow-up relative to baseline, patients
with MCI showed a greater increase in activation in the right
medial temporal lobe (right hippocampus and parahippocam-
pal gyrus) and right middle frontal gyrus than HC participants
(Figure 2C; Table A1B in Appendix).
In order to further explore the fMRI activation in the
right medial temporal lobe cluster that was observed in the
voxel-wise diagnostic group-by-time interaction, we generated
a ROI from the cluster identified in the interaction analy-
sis of NEWgtOLD (Figure 2C). The mean fMRI activation in
this region for each group at baseline and follow-up is shown
in Figure 3. As expected considering the voxel-wise results
(Figures 2A,B), a significant effect of diagnostic group on fMRI
activation is observed at baseline in the right medial temporal
lobe (Figure 3; p< 0.001) but not at the follow-up scan. Fur-
thermore, a similar significant interaction of diagnostic group-
by-time was observed in the right medial temporal lobe ROI
(Figure 3; p< 0.001) as was observed in the voxel-wise analy-
sis (Figure 2C). Additional analyses using data extracted from
“control” regions with fewer cholinergic innervations, such as the
primary motor and sensory cortices, showed no significant effects
of diagnostic group or treatment on activation at any timepoint
(data not shown).
In addition to considering the contrast of episodic encoding
relative to recognition (NEWgtOLD), we evaluated the effect of
diagnostic group and time on episodic encoding relative to rest
(NEWgtREST). This comparison employing a lower-level base-
line may detect regions that are differentially deactivated by the
encoding task (i.e., those more active at rest than during the task).
We first evaluated the effects of diagnostic group on activation
during encoding (NEWgtREST) at baseline and follow-up and
a few interesting findings were noted. MCI participants showed
significantly greater “activation” at baseline than HC participants
in a significant cluster in the bilateral medial parietal lobe [pre-
cuneus/posterior cingulate; cluster-wise significant at p< 0.05
(family-wise error (FWE) correction for multiple comparisons)],
as well as in other significant clusters in the left subthalamic
nucleus, left lentiform nucleus/globus pallidus, and right superior
parietal lobule (Figure 4A; Table A2A in Appendix). At the follow-
up scan, the medial parietal lobe region was no longer different
between MCI and HC participants. However, other regions that
were more activated in MCI than HC participants at the follow-
up scan but showed no difference between the diagnostic groups
at baseline included the left inferior parietal lobule, right cerebel-
lum, right thalamus, and right middle frontal gyrus (Figure 4B;
Table A2A in Appendix). In the interaction analysis, HC partici-
pants showed greater activation than MCI participants at follow-
up relative to baseline in the right postcentral gyrus, bilateral cere-
bellum, right putamen, right insula, right middle temporal gyrus,
and the right parietal lobe (Figure 4C; Table A2B in Appendix).
In order to further evaluate the medial parietal cluster identi-
fied in the cross-sectional analysis as showing greater “activation”
FIGURE 3 | Effect of diagnostic group and donepezil treatment on medial
temporal activation during episodic encoding relative to episodic
recognition. Values for fMRI activation were extracted from a region of
interest (ROI) in the right medial temporal lobe (right hippocampus and
parahippocampal gyrus) that was observed to be significant in the voxel-wise
analysis of the interaction of diagnostic group-by-time (left panel; also see
Figure 2C). Group means demonstrated significant effects of diagnostic
group and time. Similar to the results seen in the voxel-wise analysis
(Figures 2A,B), MCI patients (n=18) showed less activation in the right
medial temporal lobe than HC at baseline (n= 20; p<0.001) but no significant
difference between groups was observed at follow-up (p>0.05). A significant
interaction of diagnostic group-by-time was also observed (p<0.001), with
MCI patients showing more activation in the right medial temporal lobe after
donepezil treatment, as would be expected given the results of the
voxel-wise analysis (Figure 2C). MCI=mild cognitive impairment,
HC=healthy older adults, ROI= region of interest, R= right, L= left.
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FIGURE 4 | Effects of diagnostic group and time on brain activation
during episodic encoding relative to rest. (A) MCI participants (n=18)
showed significantly greater activation than HC participants (n=20) in the
medial parietal lobe (precuneus / posterior cingulate) at baseline, as well as in
other cortical and subcortical regions. (B) However, no difference between
MCI and HC participants was seen in the medial parietal region after
donepezil treatment in the MCI participants. (C) Significant clusters were also
observed in the interaction of diagnostic group-by-time analysis. All panels are
displayed at a voxel-wise threshold of p<0.01 (uncorrected) and a minimum
cluster size (k )=50 voxels. However, all observed clusters include local
maxima that meet a voxel-wise threshold of p<0.001 (uncorrected; see
Table A2 in Appendix). Further, the medial parietal lobe cluster observed in
(A) is significant at a cluster-wise threshold of p<0.05 (family-wise error
correction for multiple comparisons). See the “Results” section andTable A2
in Appendix for additional results. FU= follow-up, BL=baseline, MCI=mild
cognitive impairment, HC=healthy older adults, R= right, L= left.
at baseline in MCI patients relative to HC, we generated a ROI
from the medial parietal cluster (precuneus/posterior cingulate)
identified in the baseline comparison of diagnostic groups on the
NEWgtREST contrast (Figure 4A). The mean activations in this
region for both groups at baseline and follow-up are shown in
Figure 5. Rather than greater MCI activation, the results show that
MCI patients are deactivating significantly less than HC partici-
pants at baseline (Figure 5;p< 0.001),but the MCI and HC medial
parietal activations are similar at the follow-up scan (Figure 5;
p> 0.05). Thus, a significant interaction of diagnostic group-
by-time was observed, with MCI participants showing greater
medial parietal deactivation after donepezil treatment (Figure 5;
p< 0.001), as would be expected given the voxel-wise findings.
ASSOCIATIONS BETWEEN COGNITIVE PERFORMANCE AND fMRI
ACTIVATIONS
We evaluated the relationship between baseline, follow-up, and
change in measures of cognitive performance and fMRI activation
in the target regions of interest (right medial temporal lobe clus-
ter, medial parietal cluster) in MCI participants only. A significant
negative association between the baseline level of cognitive com-
plaints from the MCI participant (measured using the CCI) and
fMRI activation in the right medial temporal lobe at the base-
line scan was observed (Figure 6A; r =−0.482, p= 0.043). In
addition, memory performance at baseline on the CVLT short
delay recall score (Figure 6B; r = 0.529, p= 0.043) and CVLT long
delay recall score (Figure 6C; r = 0.712, p= 0.003) demonstrated
a significant positive association with fMRI activation in the right
medial temporal lobe at the post-drug follow-up scan. Finally,
greater improvement in memory performance on the CVLT short
delay recall score was associated with more deactivation in the
medial parietal cluster at the post-drug follow-up scan (Figure 6D;
r =−0.647, p= 0.009).
TASK-RELATED FUNCTIONAL CONNECTIVITY
Next, we sought to evaluate the effect of treatment with donepezil
on task-related functional connectivity of the right medial tempo-
ral lobe region identified as significant in the interaction analyses
of fMRI activation associated with episodic encoding greater than
recognition (Figure 2C). Voxel-wise analysis of the diagnostic
group-by-time interaction demonstrated a number of significant
clusters showing increased connectivity after donepezil treatment
in MCI relative to HC, including in the left superior, inferior,
and medial frontal gyri, right inferior parietal lobule, bilateral
middle frontal gyri, bilateral parahippocampal gyrus, left basal
nucleus/caudate, right posterior cingulate, bilateral postcentral
gyri, left precentral gyrus, left anterior cingulate, left superior
temporal gyrus, left claustrum, right superior parietal gyrus, left
paracentral lobule, left insula, right superior occipital gyrus, right
middle temporal gyrus, right cuneus, right cingulate, and right
cerebellum [Figure 7; multiple clusters significant at a cluster-wise
threshold of p< 0.05 (FWE), see Table A3 in Appendix].
We next extracted selected significant clusters from the
task-related functional connectivity analysis of the interaction of
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FIGURE 5 | Effect of diagnostic group and time on brain activation
in the medial parietal lobe during episodic encoding relative to
rest. Mean fMRI activation was extracted from a region of interest
(ROI) in the medial parietal lobe that was observed to be significantly
associated with diagnostic group at baseline (left panel; also see
Figure 4A). Group means demonstrated significant effects of
diagnostic group and time. Clarifying the results seen in the voxel-wise
analysis (Figure 4A), MCI patients (n=18) showed less deactivation
rather than more activation in the medial parietal lobe relative to
healthy controls at baseline (HC, n=20; p<0.001). However, no
significant difference between diagnostic groups was observed at
follow-up (similar to results in Figure 4B; p>0.05). A significant
interaction of diagnostic group-by-time was also observed (p<0.001),
with MCI participants showing more deactivation in the medial parietal
lobe after donepezil treatment. MCI=mild cognitive impairment,
HC=healthy older adults, ROI= region of interest, R= right, L= left.
diagnostic group-by-time, including significant clusters in the left
basal nucleus/caudate, left medial temporal lobe, and left frontal
lobe. Our goal was to further explore the distribution of func-
tional connectivity by diagnostic group and time in regions of the
cholinergic circuitry. The left basal nucleus/caudate (Figure 8A)
and left medial temporal lobe (Figure 8B) clusters showed a sig-
nificant effect of diagnostic group only at the follow-up scan but
not at the baseline scan (for both ROIs, baseline: p> 0.05, follow-
up: p< 0.001). At the follow-up scan, MCI participants showed
greater task-related functional connectivity in both target regions
than HC participants. However, significant effects of diagnostic
group on task-related connectivity in the left frontal region were
observed at both the baseline and the follow-up scans (Figure 8C;
baseline: p= 0.015, follow-up: p< 0.001), with HC participants
showing greater task-related connectivity at baseline and MCI
participants demonstrating greater task-related functional con-
nectivity at follow-up. As would be expected given the voxel-wise
analyses, a significant interaction of diagnostic group-by-time
was observed for all target ROIs (Figures 8A–C; p< 0.001), with
HC participants showing no change or a minor change in con-
nectivity but MCI participants showing a significant increase in
task-related functional connectivity from baseline to follow-up
(i.e., post-donepezil treatment).
ASSOCIATIONS BETWEEN COGNITIVE AND TASK PERFORMANCE AND
TASK-RELATED FUNCTIONAL CONNECTIVITY
Lastly, we assessed the association between task-related functional
connectivity measures and performance on the episodic mem-
ory fMRI task in MCI patients. Significant associations between
task-related functional connectivity and measures of overall fMRI
task accuracy were observed within the MCI group. Specifically,
improved overall task accuracy from the baseline to post-drug
follow-up visit was positively associated with increased task-
related functional connectivity in the left frontal lobe (Figure 9A;
r = 0.613, p= 0.015) and left basal nucleus/caudate (Figure 9B;
r = 0.540, p= 0.038) at the post-drug follow-up visit.
DISCUSSION
This study evaluated the effect of donepezil treatment on brain
activation in MCI patients during an episodic memory encod-
ing task. Participants with MCI showed increased activation
after treatment in the right medial temporal lobe (hippocam-
pus/parahippocampal gyrus), where they failed to activate rela-
tive to healthy older adult controls at baseline. The MCI group
also showed greater deactivation in the medial parietal lobe after
approximately 3 months of treatment with donepezil. Activation
in these regions was also associated with pre-drug and post-drug
cognitive complaints and performance. A significant increase in
task-related functional connectivity between the right medial tem-
poral lobe and the left frontal and medial temporal lobes, as
well as bilateral subcortical and cingulate regions, was observed
after treatment with donepezil in MCI patients relative to HC.
These increases in functional connectivity were also associated
with improved fMRI task performance. Overall, MCI patients
treated with donepezil appear to show “normalization” of brain
activation patterns during episodic encoding in the medial tem-
poral and medial parietal lobes similar to the activation patterns
seen in healthy older adults, as well as improved brain connectivity
in cholinergic networks.
The increased medial temporal lobe (right hippocampus and
parahippocampal gyrus) activation post-treatment observed in
MCI patients in the present study is similar to findings in pre-
vious studies of both AD and MCI patients. Previous studies
evaluating the effect of ChEIs in AD patients have observed
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FIGURE 6 | Association between cognitive complaints and performance
and brain activation in target ROIs before and after donepezil
treatment in MCI. (A) A significant negative association between the
baseline level of self-based cognitive complaints (CCI-Self), and fMRI
activation in the right medial temporal lobe at baseline was observed in MCI
participants (n= 18; r =−0.482, p=0.043). Significant associations
between baseline memory performance on the CVLT Short Delay Recall
[(B); r =0.529, p=0.043] and CVLT Long Delay Recall [(C); r =0.712,
p=0.003] and fMRI activation in the medial temporal lobe at the post-drug
follow-up scan were also observed. (D) Greater improvement in memory
performance on the CVLT Short Delay Recall was associated with more
deactivation in the medial parietal cluster at the post-drug follow-up scan
(r =−0.647, p= 0.009). Note that all medial temporal lobe values are
extracted from NEWgtOLD contrasts and all medial parietal lobe values are
extracted from NEWgtREST contrasts. Data are displayed as raw values;
however, all statistical results include age, gender, and education as
covariates. For additional information, see the Sections “Materials and
Methods” and “Results” of the manuscript. NEWgtOLD=new items
contrasted with old items (encoding> recognition), NEWgtREST=new
items contrasted with rest items (encoding> rest), ROI= region of interest,
MCI=mild cognitive impairment, HC=healthy older adults,
CVLT=California Verbal Learning Test, CCI= cognitive complaint index.
increased activation during episodic encoding after treatment in
medial and inferior temporal lobe structures, such as the hip-
pocampus, parahippocampal gyri, and fusiform gyri (15, 18). In
MCI, two previous studies have also reported increased activation
in medial temporal lobe regions during episodic encoding after
treatment with ChEI (16, 32). The laterality of observed activa-
tion (right> left) in the present study is contrary to the majority
of previous studies of episodic encoding in young adults which
have primarily implicated the left medial temporal lobe in verbal
episodic encoding (58). However, previous studies evaluating acti-
vation changes in response to treatment with ChEIs have shown
drug effects in both the left and right medial temporal lobes dur-
ing episodic encoding and recognition (16, 19). Studies of fMRI
activation during other cognitive tasks, such as a visual attention
task and a location-matching task, have also shown activation
changed in both left and right medial temporal lobes in response
to ChEI treatment in AD and MCI patients (20, 22, 23, 27). Fur-
thermore, improved cognitive performance has been associated
with increased activation in both the left and right medial tempo-
ral lobes after treatment with donepezil (31). Resting-state studies
have shown changes in the connectivity of a hippocampal net-
work and a cingulate network in the left medial temporal lobe
after treatment with ChEIs in patients with AD (28, 30). However,
a different study showed changes in connectivity of the DMN
in the right medial temporal lobe after donepezil treatment in
AD patients (33). Finally, a task-related functional connectivity
study showed increased connectivity between the left fusiform and
right hippocampus during a face encoding task (32). In sum, the
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FIGURE 7 | Interaction of diagnostic group and time on task-related
functional connectivity during episodic encoding relative to episodic
recall. MCI patients (n=18) showed a greater increase in task-related
functional connectivity in the left basal nucleus/caudate (top row), left medial
temporal lobe (top row), left frontal lobe (second row), as well as regions of
the precentral and postcentral gyri, parietal lobe, cingulate, lateral temporal
lobe, occipital lobe, and cerebellum relative to HC participants (n= 20). All
panels are displayed at a voxel-wise threshold of p<0.01 (uncorrected) and a
minimum cluster size (k )=100 voxels. However, all clusters contain local
maxima that reach a voxel-wise threshold of p<0.001 (uncorrected; see
Table A3 in Appendix). Further, numerous clusters reach a cluster-wise
significance of p<0.05 (family-wise error correction for multiple
comparisons), including clusters in the left frontal lobe, basal
nucleus/caudate, left parahippocampal gyrus, bilateral postcentral gyrus, left
precentral gyrus, right parietal lobe, anterior cingulate, left insula, left temporal
lobe, and cerebellum. See the Section “Results” and Table A3 in Appendix
for additional results. MCI=mild cognitive impairment, HC=healthy older
adults, R= right, L= left.
results to date have been mixed regarding the lateralization of ChEI
treatment-induced brain activation in MCI and AD. The observed
activation changes in the right medial temporal lobe during verbal
episodic encoding may represent de-differentiation or compen-
sation in older adults with and without cognitive impairment. A
similar pattern of loss of laterality during episodic memory has
been reported in the prefrontal cortex in cognitively healthy older
adults and patients with prodromal and clinical AD (59). Further
studies to investigate the lateralization of medial temporal lobe
activation in cognitively healthy and impaired older adult popula-
tions during verbal episodic encoding, as well as in the context of
treatment with ChEIs, is warranted. Overall, this is the first study
to compare change in brain activation during an episodic encod-
ing task in MCI patients after donepezil treatment to healthy older
adults scanned with the same fMRI protocol to control for retest
effects. The increased activation in the medial temporal lobe seen
in the present study, as well as in previous reports, suggests that
donepezil may improve brain activation in regions important to
memory function in patients with MCI and AD.
The increased deactivation during episodic encoding seen in
the medial parietal lobe after treatment with donepezil in MCI
patients has not been consistently reported in prior ChEI studies,
although a few have reported decreased precuneus/posterior cin-
gulate activation after treatment. Bokde et al. observed a decrease
in precuneus activation after drug treatment during a location-
matching task in AD patients (23). Goekoop and colleagues also
observed a decreased activation after treatment in the left posterior
cingulate during an episodic recognition task in MCI but not AD
patients (19). We highlight that the present study is the first to
demonstrate that the donepezil induced changes in this region
reflect appropriately increased deactivation in the DMN rather
than reduced task-related activation.
Resting-state connectivity studies in AD patients treated with
donepezil have evaluated functional networks which include the
medial parietal lobe, such as the DMN and a functional hippocam-
pal network. These studies have shown increased connectivity of
the DMN, a hippocampal functional network, and a posterior cin-
gulate functional network post-treatment (28, 30, 33). Improved
connectivity in functional or resting-state networks important
for memory may underlie the increased deactivation observed in
MCI patients. Again, the results suggest that treatment of MCI
patients with donepezil may somewhat “normalize” brain acti-
vation patterns during episodic encoding, resulting in a pattern
of deactivation in the medial parietal lobe and activation in the
medial temporal lobe which more closely resembles the activation
patterns of healthy older adults.
Previous reports assessing resting-state or task-related func-
tional connectivity have focused solely on AD patients treated
with ChEIs. Thus, this is the first study to evaluate task-related
functional connectivity before and after treatment with donepezil
in MCI. The observed increase in functional connectivity is similar
to the previous findings in AD patients (28, 30, 33). The observed
significant cluster in the basal nucleus/caudate is particularly
interesting,as this cluster is in close proximity to the nucleus basalis
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FIGURE 8 | Effects of diagnostic group and time on task-related
functional connectivity in selected regions of interest. Mean values of
task-related functional connectivity were extracted from three regions of
interest (ROIs) identified in the interaction analysis of diagnostic
group-by-time (left panels; also see Figure 7), including in the (A) left basal
nucleus/caudate, (B) left medial temporal lobe, and (C) left frontal lobe. Group
means demonstrated significant effects of diagnostic group and time. At
baseline, HC participants (n=20) had greater task-related functional
connectivity in the left frontal lobe (C) than MCI participants. However, at
follow-up, MCI patients showed greater task-related functional connectivity
than HC participants in all evaluated regions (A–C). As expected, a significant
interaction of diagnostic group-by-time was observed for each ROI (A–C) with
MCI participants showing a greater increase in task-related functional
connectivity between the baseline and post-treatment follow-up scans than
HC participants (p<0.001). MCI=mild cognitive impairment, HC=healthy
older adults, ROI= region of interest, R= right, L= left.
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FIGURE 9 | Association between task performance and task-related
functional connectivity in target ROIs after donepezil treatment in
MCI patients. Significant associations between improved overall task
accuracy from the baseline to post-drug follow-up scan and task-related
functional connectivity in the left frontal lobe [(A); r =0.613, p=0.015] and
left basal nucleus/caudate [(B); r =0.540, p=0.038] at the follow-up scan
were observed in MCI participants (n=18). See Sections “Materials and
Methods” and “Results” of the manuscript for further information.
MCI=mild cognitive impairment, HC=healthy older adults, ROI= region
of interest.
of Meynert, which is known to provide cholinergic innervation
to the hippocampus and shows early degeneration of cholinergic
neurons in AD (60–62). Thus, the increased task-related functional
connectivity of the right hippocampus/parahippocampal gyrus
with this region may reflect improved function of cholinergic neu-
rons from the nucleus basalis of Meynert to the hippocampus in
MCI patients after treatment. Other significant clusters, including
in the left medial temporal and frontal lobes, also provide evidence
that treatment with donepezil improves the function of cholinergic
networks during episodic encoding in MCI patients. The observed
associations of increased functional connectivity in target regions
and improved cognition further underscores the importance of
functional connections of the cholinergic network in memory and
cognition. Therefore, not only does donepezil potentially improve
local functioning of regions important for episodic encoding (i.e.,
medial temporal lobe, medial parietal lobe), but treatment of
MCI patients with donepezil may also improve the connectivity of
cholinergic networks, likely allowing for better task performance
and improved cognitive function.
The present study has a few limitations. The absence of a
placebo-controlled MCI group impedes our ability to assess the
change that may occur in the absence of treatment in MCI patients
over time. This group would be an interesting comparison group
for both treated MCI patients and HC participants. Future stud-
ies including a placebo-controlled MCI group, along with treated
MCI and HC participants, would provide additional important
information about the effects of ChEI treatment in MCI and aging.
Secondly, the relatively short-term nature of the donepezil treat-
ment in the present study (10–12 weeks) may not fully capture
any potential longer term beneficial effects of ChEI treatment
in MCI. Future research with follow-up over a longer period of
time would help to clarify the clinical and functional implica-
tions of long-term ChEI treatment. Changes in blood flow and
vascular function in response to treatment with ChEIs have been
reported in AD and MCI (30, 63–65), as well as in older adults
with or without cognitive impairment in the absence of drug treat-
ment. Therefore, any observed changes in brain activation could
be related to changes in blood flow or hemodynamic coupling
due to aging or donepezil treatment. Specifically, these changes
may affect the reliability and stability of the BOLD fMRI sig-
nal, which would complicate data interpretation. However, the
absence of significant group or drug treatment effects in “con-
trol” regions of the brain that are not highly innervated with
cholinergic pathways suggests the observed findings cannot only
be attributed to changes in blood flow. Future studies utilizing
advanced MRI techniques to measure perfusion [i.e., arterial spin
labeling (ASL)] may further clarify the relative contribution of
vascular changes in ChEI treatment effects. Finally, although the
present study is among the largest of its type, the modest sam-
ple sizes nonetheless limit statistical power and ability to assess
more complex relationships between brain activation, cognitive
performance, and genetic variations before and after donepezil
treatment. Due to the limited sample size, we chose to use a less
stringent threshold for the voxel-wise comparisons and observed
activation changes in hypothesized brain regions. However, future
studies in expanded cohorts would be beneficial and are needed to
replicate the present findings.
In sum, MCI patients treated with donepezil show increased
brain activation and deactivation in task-related regions and
increased task-related functional connectivity during episodic
encoding relative to pre-treatment baseline. Specifically, MCI
patients show increased medial temporal lobe activation, increased
medial parietal lobe deactivation, and improved task-related con-
nectivity of cholinergic networks after approximately 3 months
of cholinergic enhancement with donepezil. On-drug activation
patterns and connectivity of functional cholinergic networks in
MCI participants are similar to those observed in healthy older
adults, suggesting a possible “normalization” of brain activation
and connectivity after treatment with donepezil, effects which are
associated with memory performance and general cognition.
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APPENDIX
Table A1 | Brain activation during episodic memory encoding task (new>old).





in Cluster (k )
Cluster p
(FWE/FDR)
MNI coordinates Nearest gray matter region
X Y Z
(A) EFFECT OF GROUPAT BASELINEAND FOLLOW-UP
NEWgtOLD: BL,
HC>MCI




3.53 3.36 <0.001 26 −36 −4 Right hippocampus
NEWgtOLD: BL,
HC>MCI
3.16 3.04 0.001 24 −38 −20 Right cerebellum – culmen
NEWgtOLD: BL,
HC>MCI
4.10 3.86 <0.001 0.012 210 0.62/0.32 30 8 −24 Right uncus (BA 28)
NEWgtOLD: BL,
HC>MCI
3.28 3.14 0.001 0.038 131 0.96/0.53 −6 −4 70 Left superior frontal gyrus (BA 6)
NEWgtOLD: BL,
HC>MCI




4.31 4.03 <0.001 0.161 55 1.00/0.85 4 −34 −58 Brainstem: medulla
NEWgtOLD: FU,
HC>MCI
3.95 3.73 <0.001 0.130 65 1.00/0.85 48 −30 20 Right insula (BA 13)
NEWgtOLD: FU,
HC>MCI
3.92 3.71 <0.001 0.069 97 1.00/0.85 −52 8 14 Left precentral gyrus (BA 44)
NEWgtOLD: FU,
HC>MCI
3.88 3.67 <0.001 0.100 78 1.00/0.85 10 −82 −38 Right cerebellum – pyramis
NEWgtOLD: FU,
HC>MCI




3.31 3.17 0.001 40 −22 60 Right precentral gyrus (BA 4)
NEWgtOLD: FU,
HC>MCI
3.29 3.16 0.001 0.033 141 0.94/0.81 38 −46 6 Right caudate tail
NEWgtOLD: FU,
HC>MCI




3.21 3.08 0.001 0.050 115 0.99/0.81 −2 −28 56 Left medial frontal gyrus (BA 6)
NEWgtOLD: FU,
HC>MCI
3.11 2.99 0.001 0.022 165 0.85/0.74 28 −16 4 Right putamen
(B) INTERACTION OF GROUP XTIME
NEWgtOLD:
FU>BL, MCI>HC
3.97 3.74 <0.001 0.172 52 1.00/0.88 36 0 64 Right middle frontal gyrus (BA 6)
NEWgtOLD:
FU>BL, MCI>HC
3.83 3.63 <0.001 0.1 78 1.00/0.88 26 −26 −18 Right parahippocampal gyrus
(BA 35)
BA, Brodmann Area; BL, baseline scan; FU, follow-up scan; HC, healthy control; FWE, family-wise error correction for multiple comparisons; FDR, false discovery
rate correction for multiple comparisons; k, number of voxels in cluster; MCI, mild cognitive impairment; MNI, Montreal Neurologic Institute; unc., uncorrected for
multiple comparisons.
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Table A2 | Brain activation during episodic memory encoding task (new> rest).





in Cluster (k )
Cluster p
(FWE/FDR)
MNI coordinates Nearest gray matter region
X Y Z
(A) EFFECT OF GROUPAT BASELINEAND FOLLOW-UP
NEWgtREST: BL,
MCI>HC
4.46 4.15 <0.001 <0.001 683 0.01/0.01 8 −60 26 Right cingulate gyrus (BA 31)
NEWgtREST: BL,
MCI>HC
3.79 3.59 <0.001 −4 −66 28 Left precuneus (BA 31)
NEWgtREST: BL,
MCI>HC








3.78 3.58 <0.001 −20 −6 −10 Left lentiform
nucleus – globus pallidus
NEWgtREST: BL,
MCI>HC








3.74 3.54 <0.001 0.094 94 1.00/0.89 34 −78 −24 Right cerebellum – declive
NEWgtREST: FU,
MCI>HC
3.68 3.50 <0.001 0.069 113 0.99/0.89 6 −30 2 Right thalamus – pulvinar
NEWgtREST: FU,
MCI>HC
3.57 3.40 <0.001 0.022 193 0.80/0.89 36 12 50 Right middle frontal gyrus
(BA 6)
























3.55 3.38 <0.001 −8 −68 −36 Left cerebellum – pyramis
(Continued)
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Table A2 | Continued





in Cluster (k )
Cluster p
(FWE/FDR)




































3.69 3.51 <0.001 0.117 81 1.00/0.78 −28 32 44 Left middle frontal gyrus
(BA 9)
BOLD, significant at a cluster-wise threshold of p<0.05 corrected for multiple comparisons (FWE and/or FDR).
BA, Brodmann Area; BL, baseline scan; FU, follow-up scan; HC, healthy control; FWE, family-wise error correction for multiple comparisons; FDR, false discovery
rate correction for multiple comparisons; k, number of voxels in cluster; MCI, mild cognitive impairment; MNI, Montreal Neurologic Institute; unc., uncorrected for
multiple comparisons.
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Table A3 |Task-induced functional connectivity during episodic memory encoding (new>old).





in cluster (k )
Cluster p
(FWE/FDR)









4.63 4.46 <0.001 −38 −36 54 Left postcentral gyrus (BA 40)
NEWgtOLD:
FU>BL, MCI>HC
4.07 3.96 <0.001 −18 −8 54 Left frontal sub-gyral (BA 6)
NEWgtOLD:
FU>BL, MCI>HC
4.34 4.20 <0.001 <0.001 339 0.03/0.008 68 −24 42 Right postcentral gyrus (BA 1)
NEWgtOLD:
FU>BL, MCI>HC




3.06 3.00 0.001 52 −26 42 Right postcentral gyrus (BA 2)
NEWgtOLD:
FU>BL, MCI>HC
4.22 4.09 <0.001 <0.001 295 0.064/0.014 −30 40 12 Left frontal sub-gyral
NEWgtOLD:
FU>BL, MCI>HC




3.50 3.42 <0.001 −12 40 12 Left anterior cingulate (BA 32)
NEWgtOLD:
FU>BL, MCI>HC
4.08 3.96 <0.001 <0.001 467 0.004/0.003 −10 22 0 Left caudate (head)
NEWgtOLD:
FU>BL, MCI>HC
3.93 3.82 <0.001 −4 10 −12 Left anterior cingulate (BA 25)
NEWgtOLD:
FU>BL, MCI>HC
3.45 3.38 <0.001 −16 16 10 Left caudate (body)
NEWgtOLD:
FU>BL, MCI>HC
4.03 3.91 <0.001 <0.001 395 0.012/0.005 2 −76 −38 Right cerebellum – pyramis
NEWgtOLD:
FU>BL, MCI>HC












3.30 3.23 0.001 54 −32 60 Right postcentral gyrus (BA 2)
NEWgtOLD:
FU>BL, MCI>HC




3.13 3.07 0.001 −22 60 26 Left middle frontal gyrus
(BA 10)
(Continued)
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Table A3 | Continued





in cluster (k )
Cluster p
(FWE/FDR)








3.29 3.22 0.001 −36 −18 −8 Left claustrum
NEWgtOLD:
FU>BL, MCI>HC
3.56 3.48 <0.001 <0.001 385 0.14/0.005 −46 −40 22 Left insula (BA 13)
NEWgtOLD:
FU>BL, MCI>HC








3.51 3.43 <0.001 <0.001 347 0.27/0.008 −46 8 14 Left precentral gyrus (BA 44)
NEWgtOLD:
FU>BL, MCI>HC




3.15 3.09 0.001 −42 0 10 Left insula (BA 13)
NEWgtOLD:
FU>BL, MCI>HC




















3.23 3.17 0.001 24 −90 28 Right cuneus (BA 19)
NEWgtOLD:
FU>BL, MCI>HC
3.39 3.32 <0.001 0.020 104 0.97/0.32 6 −28 26 Right cingulate gyrus (BA 23)
NEWgtOLD:
FU>BL, MCI>HC
3.28 3.21 0.001 0.006 155 0.65/0.14 −8 −46 64 Left paracentral lobule (BA 5)
NEWgtOLD:
FU>BL, MCI>HC




2.98 2.93 0.002 0.010 132 0.83/0.20 −10 20 60 Left superior frontal gyrus
(BA 6)
BOLD, significant at a cluster-wise threshold of p<0.05 corrected for multiple comparisons (FWE and/or FDR).
BA, Brodmann Area; BL, baseline scan; FU, follow-up scan; HC, healthy control; FWE, family-wise error correction for multiple comparisons; FDR, false discovery
rate correction for multiple comparisons; k, number of voxels in cluster; MCI, mild cognitive impairment; MNI, Montreal Neurologic Institute; unc., uncorrected for
multiple comparisons.
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